Caroline Charre
Overview
Explore the profile of Caroline Charre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
450
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mchantaf G, Chaillon A, Charre C, Melard A, Gardiennet E, Guinard J, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae748.
PMID: 39872809
Background: To better understand factors associated with virologic response, we retrospectively characterized the HIV proviruses of 7 people with HIV who received long-acting cabotegravir/rilpivirine (CAB/RPV-LA) and were selected according to...
2.
Murat de Montai Q, Masseran C, Perray L, Mathian A, Dorgham K, Gorochov G, et al.
J Am Acad Dermatol
. 2025 Jan;
PMID: 39855347
Background: Cutaneous lupus erythematosus (CLE) is associated with unpredictable flares and may induce permanent damage. There is currently no biomarker routinely available in CLE. Objective: To evaluate the performance of...
3.
Degasperi E, Scholtes C, Testoni B, Uceda Renteria S, Anolli M, Charre C, et al.
J Hepatol
. 2024 Dec;
PMID: 39662705
Background & Aims: Serum HBV RNA and hepatitis B core-related antigen (HBcrAg) levels have been proposed as useful biomarkers in the management of patients with HBV; however, their role in...
4.
Charre C, Merad Y, Avettand-Fenoel V
Curr Opin HIV AIDS
. 2024 Nov;
20(1):99-108.
PMID: 39484860
Purpose Of Review: This review explores the viral reservoir landscape in individuals who control viral replication after treatment interruption (TI), designated as post-treatment controllers (PTCs). Identifying their virologic features is...
5.
Chapus F, Giraud G, Huchon P, Roda M, Grand X, Charre C, et al.
J Hepatol
. 2024 May;
81(4):609-620.
PMID: 38782119
Background & Aims: Transcription termination fine-tunes gene expression and contributes to the specification of RNA function in eukaryotic cells. Transcription termination of HBV is subject to the recognition of the...
6.
Mchantaf G, Cheret A, Melard A, Essat A, Gardiennet E, Bauer R, et al.
J Virus Erad
. 2024 Jan;
9(4):100357.
PMID: 38188640
Background: Understanding factors affecting the size and the evolution of the HIV reservoir is essential for the development of curative strategies. This study aimed to assess the impact of antiretroviral...
7.
Molinos-Albert L, Baquero E, Bouvin-Pley M, Lorin V, Charre C, Planchais C, et al.
Cell Host Microbe
. 2023 Jul;
31(8):1275-1287.e8.
PMID: 37433296
HIV-1 broadly neutralizing antibodies (bNAbs) can decrease viremia but are usually unable to counteract autologous viruses escaping the antibody pressure. Nonetheless, bNAbs may contribute to natural HIV-1 control in individuals...
8.
Charre C, Regue H, Deny P, Josset L, Chemin I, Zoulim F, et al.
J Med Virol
. 2023 Mar;
95(3):e28634.
PMID: 36879535
Hepatitis B virus (HBV) and hepatitis D virus (HDV) coinfection confers a greater risk for accelerated liver disease progression. Full-length characterization of HDV genome is necessary to understand pathogenesis and...
9.
Charre C, Lemoine S, Icard V, Maud R, Tardy J, Chiarello P, et al.
AIDS Patient Care STDS
. 2022 Oct;
36(11):413-415.
PMID: 36301263
No abstract available.
10.
Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R, et al.
Ann Rheum Dis
. 2022 Aug;
81(12):1695-1703.
PMID: 35973806
Objectives: Type-I interferons (IFNs-I) have potent antiviral effects. IFNs-I are also overproduced in patients with systemic lupus erythematosus (SLE). Autoantibodies (AAbs) neutralising IFN-α, IFN-β and/or IFN-ω subtypes are strong determinants...